Submitted:
06 October 2023
Posted:
09 October 2023
Read the latest preprint version here
Abstract
Keywords:
Introduction
- A
- The Role of Excipients in Parenteral Formulations
- B
- The Evolution of Commercial Drug Delivery Technologies
- C
- Advances in Oral Drug Delivery
- D
- Alternative Routes of Drug Delivery
- E
- Intravesical and Osmotic Drug Delivery
- F
- Conclusion
Historical Development of Advancements in Sustained-Release Drug Delivery Systems
- Early Exploration of Controlled Drug Release
- 2.
- Emergence of Matrix-Based Systems
- 3.
- The Influence of Drug Properties on Design
- 4.
- Advancements in Oral and Transdermal Delivery
- 5.
- Diversification of Delivery Routes
- 6.
- Osmotic Drug Delivery Systems
Mechanism of Sustained-Release Drug Delivery Systems: Insights from Key References
- Higuchi’s Theoretical Analysis (Reference 5)
- 2.
- Influence of Drug Properties on Design (References 2 and 9)
- 3.
- Excipients and Formulation (References 1 and 4)
- 4.
- Application-Specific Delivery Routes (References 14, 15, 16, 19, 17,18, and 21)
- 5.
- Emerging Technologies (References 24 and 6 and 22)
- 6.
- Future Directions (References 12 and 14)
Factors Affecting Sustained Release in Drug Delivery
4.1. Drug Properties and Formulation Techniques [9,25]
4.2. Excipients and Polymer Selection [1,23]
4.3. Delivery Technology [1,3,5]
4.4. Personalized Medicine Approach [23]
4.5. Release Mechanisms [5,10]
4.6. Challenges and Future Perspectives
Drug delivery technology
5.1. Nanoparticles
5.2. Microspheres
5.3. Implants
5.4. Transdermal Patches
5.5. Buccal and Sublingual Routes
5.6. Nasal Drug Delivery Systems
5.7. Ophthalmic Drug Delivery
5.8. Intravesical Drug Delivery
5.9. Conclusion
Advantages and limitations on drug delivery
- 1.
- Excipients in parental formulation. [( Reference 1)]
-
Advantages:
- Enhance drug stability and solubility.
- Enable precise control of drug release.
- Improve patient compliance for parenteral drug administration.
-
Limitations:
- May require careful selection to avoid compatibility issues.
- Limited to injectable routes, which may not be suitable for all drugs or patients.
- 2.
- Controlled Drug Delivery Systems (Reference [25])
-
Advantages:
- Enable precise control of drug release kinetics.
- Reduce side effects and enhance therapeutic efficacy.
- Prolong drug action, reducing dosing frequency.
-
Limitations:
- Complex formulation and manufacturing processes.
- Costlier compared to immediate-release formulations.
- 3.
- Advances in Oral Drug Delivery (Reference [26])
-
Advantages:
- Highly patient-friendly and convenient.
- Enhance drug absorption and bioavailability.
- Offer sustained release, improving dosing regimen.
-
Limitations:
- Gastrointestinal challenges like pH variations and enzymatic degradation.
- Not suitable for drugs with poor oral bioavailability.
- 4.
- Oral Drug Delivery of Nanomedicine (Reference [24])
-
Advantages:
- Utilizes nanocarriers for improved drug solubility and targeting.
- Enables controlled and sustained release of drugs.
- Potential for personalized medicine approaches.
-
Limitations:
- Complex formulation and characterization of nanoparticles.
- Safety concerns related to nanotoxicity.
- 5.
- Buccal and Sublingual Drug Delivery (Reference [14])
-
Advantages:
- Avoids hepatic first-pass metabolism.
- Provides rapid onset of action.
- Suitable for drugs with low oral bioavailability.
-
Limitations:
- Rapid Limited to specific drug properties and patient preferences.
- Challenges in taste masking and patient acceptance.
- 6.
- Nasal Drug Delivery Systems (Reference [15])
-
Advantages:
- drug absorption and onset of action.
- Suitable for both systemic and local drug delivery.
- Non-invasive and convenient route.
-
Limitations:
- Limited to drugs compatible with nasal mucosa.
- Potential for nasal irritation.
- 7.
- Ophthalmic Drug Delivery (Reference [16])
-
Advantages:
- Direct delivery to the eye, minimizing systemic exposure.
- Enhanced bioavailability for ocular drugs.
- Potential for extended drug release.
-
Limitations:
- Challenges in maintaining drug concentration in the eye.
- Risk of patient non-compliance.
- 8.
- Transdermal Drug Delivery (Reference [19])
-
Advantages:
- Sustained release over a prolonged period.
- Bypasses gastrointestinal and hepatic first-pass metabolism.
- Improved patient adherence.
-
Limitations:
- Limited to drugs with appropriate lipophilicity and molecular size.
- Slow onset of action for some drugs.
- 9.
- Subcutaneous Drug Delivery (Reference [20])
-
Advantages:
- Suitable for biologics and protein-based drugs.
- Provides controlled and sustained release.
- Reduced dosing frequency.
-
Limitations:
- Requires specialized delivery devices.
- Potential for injection site reactions.
- 10.
- Rectal Drug Delivery (Reference [17])
-
Advantages:
- Suitable for local and systemic drug delivery.
- Bypasses hepatic first-pass metabolism.
- Potential for sustained release.
-
Limitations:
- Patient acceptability and compliance issues.
- Limited to specific therapeutic applications.
- 11.
- Vaginal Drug Delivery (Reference [18])
-
Advantages:
- Local and systemic drug delivery options.
- Suitable for gynecological treatments.
- Reduced systemic side effects.
-
Limitations:
- Limited patient acceptance for some formulations.
- Potential for vaginal irritation.
- 12.
- Intravesical Drug Delivery (Reference [21)]
-
Advantages:
- Direct delivery to the urinary bladder.
- Effective therapy for urinary bladder diseases.
- Potential for sustained release.
-
Limitations:
- Limited to specific medical conditions.
- Challenges in maintaining drug concentration.
- 13.
- Osmotic Drug Delivery (Reference [22])
-
Advantages:
- Provides controlled and predictable drug release.
- Suitable for a wide range of drugs.
- Reduced dosing frequency.
-
Limitations:
- Requires specialized osmotic pumps.
- Limited to drugs compatible with osmotic systems.
Advances in nanotechnology
Transdermal and implantable devices
Personalized medicine
Challenge s and future directions.
Conclusion
References
- Brahmankar, D.M.; Jaiswal, S.B. Biopharmaceutics And Pharmacokinetics: Pharmacokinetics,, 2nd ed.; Vallabh Prakashan: Delhi, 2009; pp. 399–401. [Google Scholar]
- Chien, Y.W. Rate controlled drug delivery Systems, 2nd ed.; Marcel Dekker: New York, revised And expanded; 2005. [Google Scholar]
- Chauhan, M.J.; Patel, S.A. A Concise Review on Sustained Drug Delivery System and Its Opportunities. Am. J. Pharmtech Res 2012, 2, 227–238. [Google Scholar]
- Pundir, S.; Badola, A.; Sharma, D. Sustained Release matrix technology and recent advance in matrix drug delivery system: a review. International Journal of Drug Research and Technology 2013, 3, 12. [Google Scholar]
- Higuchi, T. Mechanism of sustained-action Medication: Theoretical analysis of rate of release of solid Drugs dispersed in solid matrices. J. Pharm Sci 1963, 52, 1145–114920. [Google Scholar] [CrossRef] [PubMed]
- Modi, S.A.; Gaikwad, P.D.; Bankar, V.H.; Pawar, S.P. Sustained Release Drug Delivery System: A Review. IJPRD 2011, 2, 147–160. [Google Scholar]
- Wise, D.L.; Venkatraman, S.; Davar, N.; Chester, A. An Overview of Controlled Release Systems. In Handbook of Pharmaceutical Controlled Release Technology; Marcel Dekker: New York, 2000; pp. 431–464. [Google Scholar]
- Kumar; S. ; Gupta; V.; Malodia, K. Oral Extended Release Drug Delivery System: A Promising Approach. Asian J. Pharm. Tech 2012, 2, 38–43. [Google Scholar]
- Ho, W.H.; Lee, V.H.L. Influence of drug Properties on design, Controlled Drug Delivery Fundamentals and Applications, 2nd ed.; Marcel Dekker: New York, 1987; pp. 16–25. [Google Scholar]
- Bhatt, D.C. Studies on enteric coated Sustained timed-release tablets of Metronidazole. J. Chem. Pharm. Res 2010, 2, 226–232. [Google Scholar]
- Rayaprolu, B.M.; Strawser, J.J.; Anyarambhatla, G. , Excipients in parenteral formulations: selection considerations and effective utilization with small molecules And biologics. Drug Dev. Ind. Pharm. 2018, 44, 1565–1571. [Google Scholar] [CrossRef] [PubMed]
- Vargason, A.M.; Anselmo, A.C.; Mitragotri, S. The evolution of commercial drug delivery technologies. Nat. Biomed. Eng. 2021, 5, 951–967. [Google Scholar] [CrossRef]
- Alqahtani, M.S.; Kazi, M.; Alsenaidy, M.A.; Ahmad, M.Z. , Advances in oral drug delivery. Front. Pharmacol. 2021, 12, 618411. [Google Scholar] [CrossRef] [PubMed]
- Morales, J.O.; Vuddanda, P.R.; Velaga, S. Controlled drug delivery via the buccal and sublingual routes. Fundam. Drug Deliv. 2021, 433–448. [Google Scholar] [CrossRef]
- Hussein, N.R.; Omer, H.K.; Elhissi, A.M.A.; Ahmed, W.; Ahmed, W.; Phoenix, D.A.; Jackson, M.J. C.P.B.T.-A. in M., S.E. Charalambous (Eds.), Chapter 15 – Advances in Nasal Drug Delivery Systems, Academic Press. 2020; 279–311. [Google Scholar] [CrossRef]
- Chauhan, A.; Fitzhenry, L.; Serro, A.P. Recent Advances in Ophthalmic Drug Delivery. 2022; 1–5. [Google Scholar]
- Haq, M.M.U.; Razzak, M.; Uddin, M.A.; Ahmed, N.; Shahidulla, D. , Rectal drug delivery system: an overview. Clin. Pharmacol. Biopharm. 2021, 10. [Google Scholar]
- Mahant, S.; Sharma, A.K.; Gandhi, H.; Wadhwa, R.; Dua, K.; Kapoor, D.N. , Emerging trends and potential prospects in vaginal drug delivery. Curr. Drug Deliv. 2022. [CrossRef] [PubMed]
- Thirunavukkarasu, A.; Nithya, R.; Jeyanthi, J. Transdermal drug delivery systems for the effective management of type 2 diabetes mellitus: a review. Diabetes Res. Clin. Pract. 2022, 109996. [Google Scholar] [CrossRef] [PubMed]
- Sharma, P.; Gajula, K.; Dingari, N.N.; Gupta, R.; Gopal, S.; Rai, B.; Iacocca, R.G. Subcutaneous drug delivery: a review of the state-of-the-art modelling and Experimental techniques. J. Biomech. Eng. 2022. [Google Scholar] [CrossRef] [PubMed]
- Palugan, L.; Cerea, M.; Cirilli, M.; Moutaharrik, S.; Maroni, A.; Zema, L.; Melocchi, A.; Uboldi, M.; Filippin, I.; Foppoli, A.; Gazzaniga, A. International Journal of Pharmaceutics : X Intravesical drug delivery approaches for improved therapy of urinary bladder diseases. Int. J. Pharm. X. 2021, 3, 100100. [Google Scholar] [CrossRef] [PubMed]
- Keraliya, R.A.; Patel, C.; Patel, P.; Keraliya, V.; Soni, T.G.; Patel, R.C.; Patel, M.M. , Osmotic drug delivery system as a part of modified release dosage form. ISRN Pharm 2012, 2012, 528079. [Google Scholar] [CrossRef] [PubMed]
- Lieberman, H.A.; Lachman, L.; kanig, J.L. The theory and practice of industrial pharmacy, 3rd ed.; Published by: Varghese publishing house; pp. 430–456.
- Sahoo, D.; Bandaru, R.; Samal, S.K.; Naik, R.; Kumar, P.; Kesharwani, P.; Dandela, R. in: P. Kesharwani, S. Taurin, K.B. T.-T., A. of N.N. GreishGreish (Eds.), Chapter 9 – Oral Drug Delivery of Nanomedicine, Academic Press. 2021; 181–207. [Google Scholar] [CrossRef]
- Lee, V.H.L. Controlled Drug Delivery Fundamentals and Applications: Influence of drug Properties on design, 2nd ed.; Marcel Dekker, Inc.: New York, 1987; pp. 16–25. [Google Scholar]
- Wani, M.S.; et al. Controlled Release System-A Review. 2008. [Google Scholar]
- Verma, R.; Garg, S. Current Status of Drug Delivery Technologies and Future Directions. 2001. [Google Scholar]
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).